Fresh off its $259 million Series C funding round, Alumis unveiled mid-stage data Saturday for its TYK2 inhibitor ESK-001 demonstrating strong symptomatic improvement in moderate-to-severe plaque psoriasis.
Over the weekend, at the American Academy of Dermatology annual meeting, Novartis revealed early Phase IIb data from 66 patients who had been treated with either 25 mg or 100 mg of remibrutinib, which was dosed twice-daily.
The U.S. FDA has declined to approve Viatris and Mapi Pharma’s once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the companies said on Monday.
The country is upping its specialized teams tasked with responding to future infectious disease outbreaks from five to 25.
On Friday the agency approved a label expansion for Wegovy based on a supplemental New Drug Application for the indication of reducing risks of major adverse cardiovascular events including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease.
Eli Lilly announced late-breaking results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
Topline data from the Phase III PHOENIX trial of Relyvrio, which won approval in 2022, showed no significant difference on either the primary or secondary endpoints, according to Amylyx.
The FDA will convene its Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly’s application for its Alzheimer’s disease antibody donanemab, the company announced today.
The Danish drugmaker hopes to develop amycretin in its oral and injectable form simultaneously.
Since its Change Healthcare unit was breached on Feb. 21 by a hacking group called ALPHV, also known as “BlackCat”, UnitedHealth has said it is working to restore impacted channels, and that some of its systems are returning to normal. While it has not provided a timeline for full recovery, cybersecurity analysts say that is likely quite far off.
